Literature DB >> 7570326

Management considerations in Hürthle cell carcinoma.

A Azadian1, I B Rosen, P G Walfish, S L Asa.   

Abstract

BACKGROUND: Hürthle cell tumors still pose issues concerning diagnosis and management.
METHODS: From 1984 to 1993 forty-seven patients underwent thyroidectomy, and they were diagnosed after operation to have presumptive Hürthle cell tumors. The surgical pathologic findings were reviewed. In the neoplastic group the chart was reviewed for clinical features and outcome.
RESULTS: Thirty-one patients had nonneoplastic Hürthle cell nodules. Eleven (69%) of the 16 tumors were malignant affecting 11 women and five men ranging in age from 22 to 86 years. Two patients died of cancer for a 18% rate; one patient is alive with disease. Operations were uncomplicated. Factors for adverse outcome include tumor size greater than 4 cm, woman older than 60 years of age, and complete capsular invasion on surgical pathologic findings.
CONCLUSIONS: Fine-needle aspiration biopsy demonstration of Hürthle cell lesion is an indication for operation, providing Hashimoto's thyroiditis is excluded. Our surgical practice (I.B.R.) is to perform total thyroidectomy for all Hürthle cell neoplasms, as well as jugular node sampling and adjuvant radioiodine for cancer. Stringent histologic interpretation is possible and necessary for true appreciation of Hürthle cell tumor incidence and behavior. Cancer mortality of 18% is greater than the rate (2%) of our well-differentiated thyroid cancer group.

Entities:  

Mesh:

Year:  1995        PMID: 7570326     DOI: 10.1016/s0039-6060(05)80039-x

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?

Authors:  H Chen; T L Nicol; M A Zeiger; W C Dooley; P W Ladenson; D S Cooper; M Ringel; S Parkerson; M Allo; R Udelsman
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

Review 2.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

3.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

4.  Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis.

Authors:  Connie G Chiu; Reina Yao; Simon K Chan; Scott S Strugnell; Samuel Bugis; Robert Irvine; Donald Anderson; Blair Walker; Steven J Jones; Sam M Wiseman
Journal:  Can J Surg       Date:  2012-06       Impact factor: 2.089

Review 5.  Prognostic indications for Hürthle cell cancer.

Authors:  Yevgeniya Kushchayeva; Quan-Yang Duh; Electron Kebebew; Orlo H Clark
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

6.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

7.  Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment.

Authors:  Adolfo Pisanu; Luigi Sias; Alessandro Uccheddu
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

8.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

9.  18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth.

Authors:  Mine Araz; Derya Çayır
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-05

10.  Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma).

Authors:  Qiong Yang; Zhongsheng Zhao; Guansheng Zhong; Aixiang Jin; Kun Yu
Journal:  PeerJ       Date:  2019-08-27       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.